Get consulting from Sterling
Expert and experienced consultants, 8,100+ client engagements in 60+ countries, from gap assessment to a system ready for its certification audit.
Talk to a Sterling consultant← All courses
Awareness training · Pharmaceutical GMP
FDA Drug Recall Training: Handle Complaints and Run Recalls the Way FDA Expects
If you log drug complaints, decide whether they need investigation, or would be on the recall team if a batch had to come back from the US market, FDA drug recall training prepares you for the moment it matters. The pressure points are well known: is this complaint a field alert, and does the three-working-day clock start today? Which recall class will FDA assign? How deep must the recall go, and how will you prove the effectiveness checks worked?
This training course explains how US FDA expects a drug manufacturer to handle complaints and recalls: written complaint procedures and files under 21 CFR 211.198, quality unit review, investigations, field alert reports, returned and salvaged products, and recalls under 21 CFR Part 7, from health hazard evaluation and recall class to strategy, communications, status reports and termination. A built company, JKL Pharma, with tablet and injectables sites in Mumbai and Singapore, runs through every step.
FDA drug recall training teaches how drug manufacturers supplying the US handle product complaints and recalls: complaint procedures and files under 21 CFR 211.198, investigations, field alert reports within three working days, returned drug products, and recalls under 21 CFR Part 7, including recall classes, strategy, effectiveness checks, status reports and termination.
Training a recall team? Get a quote for your organisation
Part of: Pharmaceutical GMP and GDP Training
Part of: GMP & Medical Devices
Secure payment by Stripe · for yourself or for your team
What you get
- 10 video modules
About 109 minutes, with captions. Watch at your own pace on any device.
- Practice after every module
Short questions check your understanding before you move on.
- Final exam
Multiple choice, with immediate retakes if you need them.
- Built by experts
Industry experts, domain specialist trainers and globally renowned auditors with 30+ years in ISO and GRC.
A certificate you can prove, and share
Verifiable certificate with a QR code anyone can scan, plus a digital badge to add to your LinkedIn profile.
See how verification works →Standard and edition21 CFR 211.198, 211.204, 314.81(b)(1) and Part 7
Last updated31 October 2026
Why FDA drug recall readiness matters now
A recall is judged by how fast and how completely it reaches the product, and by whether the complaint signals were acted on earlier. In February 2023 FDA warned consumers not to buy or use EzriCare artificial tears and recommended a consumer-level recall of all unexpired lots for CGMP violations, including a formulation without adequate preservative in multi-use bottles. CDC had identified 55 patients in 12 states by 31 January 2023, with one death and permanent vision loss, and the products were placed on import alert.
Recalls can also cover a whole product class. In April 2020 FDA requested the immediate market withdrawal of all prescription and over-the-counter ranitidine products, because levels of the impurity NDMA increase over time and with heat. When a request like that arrives, a manufacturer needs distribution records, a recall strategy and communications ready, not drafted on the day.
Who this FDA drug recall training course is for
The course is for everyone who receives complaints or takes part in a recall at a company supplying drugs to the US. Take it when you join a complaint or quality role, before an FDA inspection, after a finding on complaint handling or field alerts, or before your next mock recall.
- Quality assurance and quality control staff
- Complaint handlers and medical information staff who receive product complaints
- Regulatory affairs staff who submit field alert reports
- Supply chain, distribution and customer service teams
- Anyone with a role in a drug manufacturer's or packager's recall procedure
What you will learn on this training course
The outcomes follow a complaint from the first call to the end of a recall, so each one maps to a step in your procedures.
- Explain what FDA requires of a drug complaint procedure and complaint file
- Decide when a complaint needs an investigation and when a field alert report is due
- Handle returned drug products and link complaints to CAPA and trends
- Describe recall classes I, II and III and how FDA classifies a recall
- Plan a recall strategy, communications, effectiveness checks and status reports
- Recognise the complaint and recall failures FDA cites in warning letters
Course outline: 10 modules
- Module 1, Why complaints and recalls matter: two US cases, the rules in brief, the built company and three myths.
- Module 2, The US rules at a glance: complaint files, investigations, field alerts, adverse experiences and Part 7.
- Module 3, Receiving and recording complaints: every channel, what counts as a complaint, the record, where it is kept and for how long.
- Module 4, Evaluating and investigating complaints: quality review, the field alert clock, thorough investigations and decisions not to investigate.
- Module 5, Field alert reports: what triggers one, who sends it, counting three working days, and what to send.
- Module 6, Returned and salvaged products: holding returns, when doubt means destruction, the returns record and salvaging.
- Module 7, Recalls under Part 7: recall terms, the three classes, health hazard evaluation, and firm-initiated or FDA-requested recalls.
- Module 8, Recall strategy and communications: depth of recall, public warnings, effectiveness checks and the recall letter.
- Module 9, Running and closing a recall: status reports, accounting for product, termination and the records that make recalls work.
- Module 10, What FDA cites and a rehearsal: real warning letter findings, a full recall rehearsal and a site checklist.
The FDA complaint and recall requirements explained
Complaint handling for drugs is a CGMP requirement. 21 CFR 211.198 requires written procedures for handling all written and oral complaints, review by the quality control unit, a decision on investigation under 211.192, and a complaint file kept for the required period. Complaints that may be adverse drug experiences must also be reviewed under the postmarketing reporting rules. 21 CFR 211.204 covers returned drug products and 211.208 salvaged products.
Under 21 CFR 314.81(b)(1), holders of drug applications must submit a field alert report within three working days of receiving information about certain quality problems in distributed product, such as contamination, significant chemical or physical change, or failure of a distributed batch to meet specifications. Recalls follow 21 CFR Part 7, subpart C: FDA assigns Class I, II or III after a health hazard evaluation, and the firm sets a recall strategy covering depth, public warning and effectiveness checks, then reports status until FDA terminates the recall. FDA's March 2022 guidance on voluntary recalls is named as the current guidance.
How the online course works
The course is delivered as 10 on-demand video modules with about 2 hours of video in total. Each module ends with short practice questions so you can check your understanding before moving on; they do not count toward your result. Module 10 runs a full recall rehearsal at JKL Pharma, from the first complaint to termination, so you can see every step in sequence.
The course closes with a multiple-choice final exam drawn from the course's question bank. The exam is assessed, with a pass mark of 70%. If the first attempt does not reach it, one retake is included. Every learner who completes the course and the exam receives a Sterling Academy Certificate of Completion.
- Study online, on demand, on any device: laptop, tablet or phone
- Learn at your own pace and replay any module
- Practice questions after every module
- Final multiple-choice exam with one retake
- Certificate of Completion when you finish the course and exam
What you can do after the course
You will be able to check your own complaint and recall system against what FDA expects.
- Record a complaint completely, whichever channel it arrives through
- Decide whether a complaint needs a thorough investigation and document the decision
- Spot field alert triggers and meet the three-working-day deadline
- Handle returned goods so nothing re-enters stock without a quality decision
- Prepare a health hazard evaluation and propose a recall strategy
- Plan effectiveness checks and status reports through to termination
- Run a mock recall and act on what it reveals
FDA drug recall training for teams and organisations
Sterling Academy offers company plans so a whole team can take this course together. A client administrator in your organisation adds people, assigns this course and related ones, and follows progress from one place, so QA, complaint handlers, regulatory and supply chain staff can all work from the same method.
Progress reports show who has started, who has completed and who holds a certificate, which is useful evidence of training when an auditor or inspector asks for it. Your organisation receives one invoice for the plan instead of individual receipts. Company prices are set per organisation: get a quote for your organisation and we will reply with a plan that fits the number of learners and courses you need.
Why learn with Sterling Academy
Sterling Academy courses are built by industry experts, domain specialist trainers and globally renowned auditors with 30+ years of experience in ISO and GRC. The Academy is the training arm of Sterling International Consulting, with 8,100+ client engagements in 60+ countries over 20+ years, so the course content reflects what auditors, inspectors and clients actually ask for in practice.
Every course is kept to the current text of the regulations and guidance it teaches; this one uses the eCFR text read in October 2026 and FDA's field alert questions and answers of July 2021.
Preview this course
Experience the learning
before you enrol.
Watch a sample from Drug Complaints and Recalls Training (US FDA) before you enrol.
Drug Complaints and Recalls Training (US FDA)Sample
Inside the course
A clear path through the essentials.
10 modules, 10 practice checkpoints and a final exam. Video runtimes are approximate; allow additional time for the practice questions and the final exam. Modules marked optional can be skipped; the others are studied in any order.
Part 1Why complaints and recalls matter and the FDA rulesApprox. 22 min
- Welcome: why complaints and recalls matter11 min
US FDA drug complaint handling and recalls: the EzriCare eye drop recall, the ranitidine withdrawal, and how the US rules form one chain.
What this module covers
Opens with what can happen in the three days after a pharmacist's call. Covers the February 2023 recall of EzriCare Artificial Tears, with the CDC linking 55 patients in twelve states to the drops, and FDA's April 2020 request to withdraw a whole class of medicines. Sets out the US rules as one chain, from the complaint file to field alert reports and recalls. Introduces JKL Pharma Ltd, its complaint unit in Mumbai and US agent, and outlines the ten modules and the final exam. You see why the impurity NDMA led FDA to ask for all ranitidine products to be withdrawn in April 2020, and you meet other firms such as an injectables maker in New York and a contract packager in Boston. A recap closes the module: every complaint, recorded and reviewed.
What you will be able to do
- Explain how complaints, field alerts and recalls link into one chain
- Recognise early complaint signals that point to a wider problem
- Describe the US rules that apply to a drug manufacturer
Why it matters
A single call from a pharmacist can start several regulatory clocks; seeing the whole chain helps you act in time.
Practice: Practice: Welcome: why complaints and recalls matter · 3 questions
- The US rules at a glance11 min
US FDA rules for drug complaints and recalls at a glance: 21 CFR 211.198, 211.192, field alert reports under 314.81, and Part 7.
What this module covers
Begins with a hospital pharmacist reporting cloudy ceftriaxone vials and the questions JKL Pharma's quality team must answer before lunch. Covers section 211.198 on complaint procedures, 211.192 on investigations that reach other batches, 314.81 on field alert reports within three working days, and Part 7 on recall policy. Adds returned products, the annual product review and adverse drug experience reports. Shows JKL Pharma's process map, then a contract packager in Boston and an injectables firm in New York. You see how an FDA investigator picks one complaint and follows it through the chain. The module ends with a recap of the rules for complaints, the two kinds of report, and recalls under Part 7: one chain, several rules, clear owners.
What you will be able to do
- Identify which US rule covers each step from complaint to recall
- Explain who reports to FDA when a contract packager is involved
- Map your own site's complaint and recall process to the rules
Why it matters
Knowing which rule answers which question saves time when the pressure is on and the three working days are running.
Practice: Practice: The US rules at a glance · 3 questions
Part 2Taking in and investigating drug complaintsApprox. 21 min
- Receiving and recording complaints10 min
Drug complaint intake under 21 CFR 211.198: written procedures for written and oral complaints, a complete complaint record, and file retention.
What this module covers
Starts with a call to JKL Pharma's US agent about a cracked ceftriaxone vial, written on a sticky note and forgotten until a second hospital calls. Reads section 211.198 on written procedures for all written and oral complaints, and the complaint file. Shows JKL Pharma's call script, its intake steps and routing to the quality unit in Mumbai. Covers what each record holds, keeping the file at the site or readily available, retention after expiry or receipt, and a Toronto tablet maker's head office file. You see how JKL's agents record the complaint in the caller's own words, ask whether a patient was affected, and ask for the vial to be kept. The module closes with a recap: record first; judge after.
What you will be able to do
- Record every written and oral complaint, however small
- Check that a complaint record holds the facts the rule asks for
- Explain where the complaint file is kept and for how long
Why it matters
A complaint that is never recorded cannot be reviewed, trended or investigated, and may be the first warning of a real problem.
Practice: Practice: Receiving and recording complaints · 3 questions
- Evaluating and investigating complaints11 min
Drug complaint evaluation and investigation under 21 CFR 211.198 and 211.192: quality unit review, scope to other batches, and no-investigation records.
What this module covers
Opens with dark specks reported on JKL Pharma's metformin 500 milligram tablets from lot M-2610. Reads section 211.198 on quality unit review of any complaint involving a possible failure to meet specifications, and the link to 211.192. Shows how JKL Pharma's quality unit in Mumbai evaluates the complaint and follows the investigation into reserve samples, batch records and complaint history. Applies the same reasoning at a capsule maker in Frankfurt and an ingredient supplier in Hong Kong, and covers recording a decision not to investigate. You see JKL's written evaluation procedure and why a possible failure, not a confirmed one, is enough for review. A recap closes the module: evidence before conclusions.
What you will be able to do
- Decide when a possible failure needs a full investigation
- Extend an investigation to other batches and associated products
- Record the reason and the decision-maker when no investigation is made
Why it matters
One complaint about one bottle may be the first sign of a batch problem; evidence before conclusions keeps patients safe.
Practice: Practice: Evaluating and investigating complaints · 3 questions
Part 3Field alerts and returned productsApprox. 22 min
- Field alert reports11 min
FDA field alert reports (FARs) under 21 CFR 314.81: triggers, who reports, counting three working days from receipt, and what to submit.
What this module covers
Begins on a Friday afternoon at JKL Pharma's Singapore site, when a contract laboratory reports a ceftriaxone stability sample failing sterility on a lot already on the US market. Reads section 314.81 and FDA's July 2021 guidance, and the two kinds of information that trigger a report. Shows how to count the days from receipt, not confirmation, why JKL's quality agreement asks for a same-day call, and which FDA office to use. Covers a stopper supplier in Tokyo and the initial, follow-up and final reports. You see how the days are counted when bad news arrives on a Friday, and what goes into the report. The module ends with a recap: three working days, from receipt.
What you will be able to do
- Decide whether a quality problem triggers a field alert report
- Count three working days from the receipt of information
- Explain what goes into initial, follow-up and final reports
Why it matters
Waiting for the root cause before reporting is a common failure; the clock starts when information arrives, not when it is confirmed.
Practice: Practice: Field alert reports · 3 questions
- Returned and salvaged products11 min
Returned and salvaged drug products under 21 CFR 211.204 and 211.208: holding, testing, records, destruction and the salvaging ban.
What this module covers
Opens with forty cartons of amoxicillin capsules returned for overstock, after three days in a trailer in July. Covers section 211.204: returned products identified and held under written procedures, destroyed when their history casts doubt unless testing shows they meet standards, and records of reason, quantity and disposition. Explains the rule on salvaging after disasters, fires, accidents or equipment failures. Shows JKL Pharma's returns steps and decision guide, a London generics firm's misprinted labels and a Paris brand's flooded warehouse. You see how JKL's decision guide helps staff decide what happens to a return, and why returned stock never goes back on the shelf before quality has seen it. A recap closes the module: doubt means destroy, or show.
What you will be able to do
- Identify and hold returned product until quality decides
- Decide when a returned product must be destroyed or tested
- Explain why products exposed in a disaster are not salvaged
Why it matters
A clean, sealed carton can still hide damage from where it has been; doubt means destroy, or show it meets standards.
Practice: Practice: Returned and salvaged products · 3 questions
Part 4Running an FDA recall from class to closureApprox. 44 min
- Recalls under Part 711 min
FDA drug recalls under Part 7: recall definitions, Class I, II and III, health hazard evaluation and how a firm notifies FDA of a recall.
What this module covers
Returns to JKL Pharma's metformin specks, now traced in the built example to metal particles from a worn press part in three lots on the US market. Covers section 7.40 on recall as a voluntary action and an alternative to court action, and the difference between a recall, a correction, a market withdrawal and stock recovery. Explains how FDA evaluates the hazard and assigns class one, two or three, who owns the recall, the nine facts a firm reports and FDA's weekly Enforcement Report. You see JKL's template with all nine facts, so that nothing is missing on the first call to FDA. The module closes with a recap: the violation decides the word.
What you will be able to do
- Tell a recall from a market withdrawal or stock recovery
- Explain how FDA assigns a recall class after its hazard evaluation
- Notify FDA of a recall with all nine facts on the first call
Why it matters
Calling a recall a market withdrawal means FDA is never told; choosing the right word depends on the violation.
Practice: Practice: Recalls under Part 7 · 3 questions
- Recall strategy and communications10 min
FDA recall strategy under sections 7.42 and 7.49: recall depth, public warnings, effectiveness check levels, and writing the recall letter.
What this module covers
Continues JKL Pharma's metformin recall, where the committee debates recalling from wholesalers only or from pharmacies too. Defines a recall strategy and its three parts, then the five factors in section 7.42 that shape it. Shows JKL choosing the retail level and effectiveness check level A because the particles are hard to see, its letter to pharmacies and its calls after five days. Covers the recall message, a clearly marked, brief and specific letter, and how a Boston wholesaler handles the notice. You see the outline of JKL Pharma's letter to pharmacies and how FDA lists each new recall in its weekly Enforcement Report. The module ends with a recap: the hazard sets the depth.
What you will be able to do
- Set the depth of a recall from the hazard and the distribution
- Choose an effectiveness check level and plan follow-up calls
- Write a recall letter that is clear, brief and specific
Why it matters
A recall that stops at the wholesaler can leave stock on pharmacy shelves; the hazard sets the depth.
Practice: Practice: Recall strategy and communications · 3 questions
- Running and closing a recall11 min
Running and closing an FDA drug recall: status reports under 21 CFR 7.53, product reconciliation, recall termination and distribution records.
What this module covers
Looks in on JKL Pharma's recall in its third week, with built figures: eighty-eight percent of pharmacies have replied and twelve percent are silent. Covers section 7.53 on periodic status reports, generally every two to four weeks, and the six items they contain. Shows JKL reconciling the product, chasing silent pharmacies, destroying returns and fixing the worn press part. Explains termination in writing by FDA, recall plans, positive lot coding and distribution records, with a Frankfurt firm's yearly mock recall. You see JKL's reconciliation, its destruction records and its corrective action on the press, with a call on day five added to its plan. A recap closes the module: FDA terminates; you account.
What you will be able to do
- Prepare a recall status report with the six items FDA asks for
- Reconcile recalled product so every lot is accounted for
- Explain when and how FDA terminates a recall
Why it matters
A recall is only as good as its gaps; the pharmacies that never reply are the ones still holding stock.
Practice: Practice: Running and closing a recall · 3 questions
- What FDA cites, a rehearsal and your exam12 min
FDA warning letter findings on drug complaint handling under 21 CFR 211.192, a full recall rehearsal, and a checklist for your site.
What this module covers
Opens with FDA's September 2024 warning letter to Azurity Pharmaceuticals in Massachusetts, where about eighty-six complaints went unevaluated until the inspection, and the April 2024 letter to Westwood Laboratories in California. Draws four patterns: trends not seen, scope too narrow, samples unused and alerts sent late. Runs JKL Pharma's yearly recall rehearsal, including its day three field alert on Form FDA 3331a and the actions that followed. Ends with a checklist for your site, the final exam and the Certificate of Completion. You see JKL's answers to the rehearsal scenario, each linked to the module where it was taught, and who does what. The course closes with a recap: record, investigate, report, account.
What you will be able to do
- Recognise the four patterns FDA cites in complaint handling
- Run a recall rehearsal from complaint to termination
- Use a checklist to find gaps at your own site
Why it matters
Complaints often arrive months before an inspection; a yearly rehearsal finds the gaps before FDA does.
Practice: Practice: What FDA cites, a rehearsal and your exam · 3 questions
Frequently asked questions
Your questions,
answered.
About Drug Complaints and Recalls Training (US FDA), its certificate and enrolment.
Ask SterlingIs Sterling Academy a good choice for US FDA cGMP training?
Yes. Sterling Academy's US FDA cGMP courses are built by the Sterling consulting group, which has taken organisations to certification across 8,100+ client engagements in 60+ countries over 20+ years. They cover the awareness, implementation and specialist levels, always on the current edition, with practice questions that show the right answer. Each course ends with a final exam and a verifiable certificate that anyone can check online, plus a LinkedIn badge, and client administrators can show an auditor exactly who has been trained. You will understand what US FDA cGMP asks of you, contribute to your organisation's implementation and audit readiness, and play your part with confidence when the auditor visits. Sterling Academy courses carry the same content as Sterling's classroom training, whose certificates are trusted and accepted by all major certification bodies, as evidence of training at client audits for over 20 years.
Awareness: US FDA GMP Awareness for Pharmaceuticals (21 CFR Parts 210 and 211) · Implementation: US FDA Current Good Manufacturing Practice (cGMP) Implementation for Pharmaceuticals (21 CFR Parts 210 and 211) · Specialist: Aseptic Processing Training (US FDA)
What is FDA drug recall training?
It is training on how drug manufacturers supplying the US handle product complaints and recalls. This course covers complaint procedures and files under 21 CFR 211.198, investigations, field alert reports, returned products, and recalls under 21 CFR Part 7, from health hazard evaluation and class to strategy, effectiveness checks and termination.
Who needs FDA drug recall and complaint training?
Anyone who receives complaints or has a role in a recall needs it: QA and QC staff, complaint handlers, regulatory affairs, supply chain, distribution and customer service teams at drug manufacturers and packagers supplying the US. Training every member on the same procedure means nobody learns the steps for the first time during a real recall.
What is a field alert report?
A field alert report tells FDA about certain quality problems in a distributed drug, such as contamination, significant chemical or physical change, or a batch failing specifications. Under 21 CFR 314.81(b)(1) it is due within three working days of receiving the information. Module 5 explains the triggers and how to count the days.
What are FDA recall classes I, II and III?
Class I covers products with a reasonable probability of causing serious adverse health consequences or death; Class II covers temporary or medically reversible consequences or a remote probability of serious ones; Class III covers products unlikely to cause adverse health consequences. FDA assigns the class after a health hazard evaluation.
How long does the course take?
The course has about 2 hours of video across 10 modules. It is on demand, so complaint and recall team members can complete it in short sessions between other duties and replay any module before a mock recall or an inspection.
Is complaint handling mandatory under FDA GMP?
Yes. 21 CFR 211.198 requires written procedures for all written and oral complaints about a drug product, review by the quality control unit, a documented decision on investigation, and a complaint file. FDA reviews complaint files during inspections and cites gaps in warning letters.
Do I get a certificate?
Yes, you receive a Sterling Academy Certificate of Completion. The course ends with an assessed scenario-based multiple-choice exam drawn from the question bank, with a pass mark of 70% and one retake; every learner who completes it receives the Certificate of Completion.
How much does FDA drug recall training cost?
The course costs US$19 per learner, including all 10 video modules, practice questions, the final exam and the certificate. For recall and quality teams, contact us for a quote for your organisation; company plans include a client administrator, progress reports and one invoice.
What is the difference between a recall and a market withdrawal?
A recall removes or corrects a marketed product that FDA considers in violation of the law; a market withdrawal removes or corrects a product for a minor violation that FDA would not act on, or for no violation at all. Module 7 explains these Part 7 terms and stock recovery.
What is the difference between this course and the EU GMP recall course?
This course follows US FDA rules: 21 CFR 211.198, field alert reports and Part 7. Sterling Academy's Complaints and Product Recalls Training (EU GMP) covers the EU requirements. Companies supplying both markets work under both sets of rules, and the reporting routes and terms differ.
Can my recall team take the course together?
Yes, through a Sterling Academy company plan. A client administrator adds your QA, regulatory, supply chain and customer service staff, assigns the course, and follows progress reports, and your organisation receives one invoice. Contact us for a quote for your organisation.
Your certificate
Prove what you learned.
Share it with confidence.
You will understand what US FDA cGMP asks of you, contribute to your organisation's implementation and audit readiness, and play your part with confidence when the auditor visits. Your certificate can be verified online in seconds, so certification body auditors, employers and clients can confirm your training instantly.
Complete the course and its final exam and you receive a Sterling Academy Certificate of Completion, verifiable online by QR code, with a LinkedIn badge to share.
- Pass mark
- 70%
- Prerequisites
- None
Sterling Academy courses carry the same content as Sterling's classroom training, whose certificates are trusted and accepted by all major certification bodies, as evidence of training at client audits for over 20 years.
Ask about course requirementsYour next step
Not sure which course?